Experienced in Chronic T-Cell Leukemia (CTCL)

Dr. Attaya Suvannasankha

Hematology Oncology | Hematology | Oncology
University Medical Diagnostic Associates Inc
550 N University Blvd, 
Indianapolis, IN 
Accepting New Patients
Experienced in Chronic T-Cell Leukemia (CTCL)
University Medical Diagnostic Associates Inc
550 N University Blvd, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Attaya Suvannasankha is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Suvannasankha is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Suvannasankha is currently accepting new patients.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health Ball Memorial Hospital
Iu Health West Hospital
Indiana University Health North Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
550 N University Blvd, Indianapolis, IN 46202
Other Locations
IU HEALTH MEDICAL GROUP LLC
1701 N Senate Blvd, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
Role of Osteocytes in Myeloma Bone Disease
Role of Osteocytes in Myeloma Bone Disease
Enrollment Status: Completed
Publish Date: September 08, 2023
View 4 Less Clinical Trials

44 Total Publications

EXPRESS: Bispecific T-cell Engagers for Relapsed/Refractory Multiple Myeloma After Solid Organ Transplantation: A Case Series.
EXPRESS: Bispecific T-cell Engagers for Relapsed/Refractory Multiple Myeloma After Solid Organ Transplantation: A Case Series.
Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research
Published: July 29, 2025
Similar Doctors
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Naveed M. Chowhan
Hematology Oncology | Oncology
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Naveed M. Chowhan
Hematology Oncology | Oncology

Jackson County Schneck Memorial Hospital

411 W Tipton St, Schneck Medical Center, 
Seymour, IN 
 (58.7 miles away)
812-522-2349
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Naveed Chowhan is a Hematologist Oncology specialist and an Oncologist in Seymour, Indiana. Dr. Chowhan has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Non-Hodgkin Lymphoma, Hereditary Resistance to Anti-Vitamin K, and Bone Marrow Aspiration. Dr. Chowhan is currently accepting new patients.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Danielle M. Doyle
Hematology Oncology | Hematology | Oncology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Danielle M. Doyle
Hematology Oncology | Hematology | Oncology

Indiana University Health Southern Indiana Physicians LLC

719 W 2nd St, 
Bloomington, IN 
 (46.7 miles away)
888-484-3258
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Danielle Doyle is a Hematologist Oncology specialist and a Hematologist in Bloomington, Indiana. Dr. Doyle is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. Doyle is currently accepting new patients.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Huda S. Salman
Hematology Oncology | Hematology | Oncology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Huda S. Salman
Hematology Oncology | Hematology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (1.2 miles away)
888-484-3258
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Huda Salman is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Salman is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Burkitt Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Salman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Suvannasankha's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 50 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile